Next-gen obesity biotech BioAge Labs to raise $198M in IPO
A California biotech that began as an anti-aging company, then licensed an Amgen heart failure drug for $1 million upfront and repurposed it as a weight loss therapy, has lined up a $198 million IPO....
View ArticleBarcelona VC firm Asabys raises second fund, adding to Europe’s biotech...
Asabys Partners said Thursday it closed its second health innovation fund at €180 million, or about $200 million. The Barcelona-based VC firm’s raise expands the money available to biotech and health...
View ArticleClik here to view.
Flagship launches startup to design and make lipid nanoparticles for genetic...
Flagship Pioneering is betting $50 million that it can solve one of genetic medicine’s biggest problems — how to get the therapies to the right place in the body. Its new startup, Mirai Bio, was...
View ArticleClik here to view.
EnGene unveils first set of pivotal data for NMIBC therapy
A small US and Canadian gene therapy biotech has released a look at data from its experimental bladder cancer treatment, hoping to enter a field that includes CG Oncology, ImmunityBio, Johnson &...
View ArticleBiogen walks away from Sage's essential tremor drug after mid-stage flop,...
Biogen is saying goodbye to part of its tie-up with Sage Therapeutics after the duo’s experimental medicine failed a Phase 2 essential tremor study this summer. That July flop left the drug’s future up...
View ArticleClik here to view.
Merck, Evaxion expand collaboration with infectious disease vaccine pact
Merck has inked an option and license agreement with Evaxion Biotech for two of its AI-designed vaccine candidates, bolstering an existing relationship between the drugmakers. Under Thursday’s deal,...
View ArticleA Parkinson's drug that AbbVie acquired from Cerevel succeeds in another Phase 3
AbbVie once again reported positive Phase 3 data for a Parkinson’s disease drug that was acquired from its Cerevel buyout, this time as a monotherapy. Topline data show that both doses of tavapadon...
View ArticleARCH, biotech's star slugger, snags another $3B for 13th fund
Bob Nelsen will tell you that ARCH Venture Partners is always chasing home runs. The early-stage VC firm has backed some of the most recognizable names in drug development, like Alnylam, bluebird bio...
View ArticleCSL Seqirus inks fifth contract with BARDA, making the partnership now worth...
CSL Seqirus has secured a fresh $121.4 million contract with the US Biomedical Advanced Research and Development Authority to manufacture and supply its adjuvanted vaccine against avian flu, bringing...
View ArticleClik here to view.
Instacart partners with 9amHealth to combine weight loss drugs with healthy...
The GLP-1 prescription startup 9amHealth is partnering with grocery delivery service Instacart to incorporate stipends for healthy foods into its treatment plans for diabetes, weight loss and heart...
View ArticleRepair, Genevant ink deal worth up to $107M; 858 Therapeutics raises $50M
Plus, news about Enanta, Inventiva, Eradivir, Novo Nordisk, Evotec, Lundbeck, Iambic Therapeutics and Wave Life Sciences: Genevant Sciences, Repair Biotechnologies team up: The biotechs will work on a...
View ArticleSIGA is 'deeply angered' by former exec's 'inaccurate' comments about mpox...
SIGA Technologies said former chief medical officer Jay Varma’s comments about the company’s experimental mpox drug are “inaccurate and misleading.” The infectious disease drugmaker had already fired...
View ArticleAGC Biologics to lay off 95 workers; Vertex taps Lonza to manufacture Casgevy
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. AGC Biologics said it is laying off a total of 95 staffers, which...
View ArticleUpdated: FDA adcomm votes to limit Opdivo, Keytruda use in stomach,...
The FDA’s Oncologic Drugs Advisory Committee on Thursday voted 10-2 with one abstention that Merck’s Keytruda and Bristol Myers Squibb’s Opdivo are not beneficial as a first-line treatment for stomach...
View ArticleClik here to view.
Genentech's blood cancer drug Gazyva moves toward more indications in immunology
Genentech plans to expand the label for its CD20-targeting antibody Gazyva following positive late-stage data in an autoimmune disease that impacts the kidneys. In the Phase 3 REGENCY study, a higher...
View ArticleInsilico Medicine, an early force in AI-driven drug R&D, lets IPO plans peter...
One of the original AI-driven drug discovery and development biotechs has let its plans to list on the Hong Kong stock exchange lapse for the second time in as many years. Insilico Medicine, a...
View ArticleClik here to view.
AstraZeneca's lung cancer blockbuster Tagrisso wins label expansion in...
AstraZeneca’s blockbuster lung cancer treatment Tagrisso scored a new FDA approval on Thursday in certain EGFR-mutated early-stage patients whose non-small cell lung cancer has not spread, but can’t be...
View ArticleClik here to view.
FDA lifts hold on Biomea’s diabetes trials
The FDA lifted a clinical hold on two trials testing Biomea Fusion’s diabetes treatment. The news, announced Thursday, sent the company’s shares $BMEA up by about 4% to $9.11, inching closer to its...
View ArticleClik here to view.
FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for...
The FDA on Thursday approved Bristol Myers Squibb’s new schizophrenia drug in one of the year’s most anticipated regulatory decisions. The approval gives Bristol Myers a significant foothold in the...
View ArticleClik here to view.
Endpoints 11 winner Capstan Therapeutics: Trying to win the in vivo CAR-T race
↑ CEO Laura Shawver Total raised $340 million Headquarters San Diego, CA Turning a patient’s own cells into powerful disease combatants — without the complexity of removing them from the body to do so...
View Article